Belgian observational drug utilization study of pimecrolimus cream 1% in routine daily practice in atopic dermatitis

Dermatology

Volumn 217, Issue 2, 2008, Pages 156-163

  De Backer, Marc ^a   Morren, Marie Anne ^b   Boonen, Hugo ^d   Boyden, Bert ^e   Vertruyen, Andre ^b   Lecomte, Pascal ^a   Paquay, Catherine ^a   Lesaffre, Emmanuel ^c   Lambert, Julien ^f  

^a Novartis Pharma   (Belgium)

^b UZ St Rafaël ^*

^c UNIVERSITY OF LEUVEN   (Belgium)

^d Dermatology   (Belgium)

^e Dermatology   (Belgium)

^f ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Atopic dermatitis; Corticosteroid prescription; Observational study; Pimecrolimus

Indexed keywords

CORTICOSTEROID; EMOLLIENT AGENT; PIMECROLIMUS;

ADOLESCENT; ADULT; APPLICATION SITE BURNING; APPLICATION SITE ERUPTION; APPLICATION SITE ERYTHEMA; APPLICATION SITE IRRITATION; APPLICATION SITE PAIN; APPLICATION SITE PRICKLING; APPLICATION SITE REACTION; APPLICATION SITE STINGING; ARTICLE; ATOPIC DERMATITIS; BELGIUM; CHILD; CLINICAL PRACTICE; CREAM; DRUG EFFECT; DRUG EFFICACY; DRUG USE; DRUG WITHDRAWAL; FEMALE; GENERAL CONDITION IMPROVEMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OPEN STUDY; PARENTS INDEX QUALITY OF LIFE ATOPIC DERMATITIS; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE INDEX ATOPIC DERMATITIS; REIMBURSEMENT; SCORING SYSTEM;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; BELGIUM; CHILD; CHILD, PRESCHOOL; CONFIDENCE INTERVALS; DERMATITIS, ATOPIC; DERMATOLOGY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG UTILIZATION; EMOLLIENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; MALE; MULTIVARIATE ANALYSIS; PROBABILITY; QUALITY OF LIFE; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TREATMENT OUTCOME;

EID: 49649126627     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000136654     Document Type: Article

References (13)

1. McKenna SP, Whalley D, Dewar AL, Erdman RAM, Kohlmann T, Niero M, Baro E, Cook SA, Crickx B, Frech F, van Assche D: International development of the Parents' Index of Quality of Life in Atopic Dermatitis (PIQoL-AD). Qual Life Res 2005;14:231-241.
2. Whalley D, McKenna SP, Dawar AL, Erdman RA, Kohlmann T, Niero M, Cook SA, Crickx B, Herdman MJ, Frech F, van Assche D: A new instrument for assessing quality of life in atopic dermatitis: international development of the Quality of Life Index for Atopic Dermatitis (QoLIAD). Br J Dermatol 2004;150:274-283.
3. Cleemput I: Validation of two disease-specific quality of life questionnaires for atopic dermatitis in Belgium. Final report. Meise, Health Economics Disease Management (HEDM), January 13, 2004.
4. Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, Dobozy A, Paul C, Molloy S, Hultsch T, Graeber M, Cherill R, de Prost Y: Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002;110:1-8.
5. Meurer M, Fölster-Holst R, Wozel G, Weidinger G, Jünger M, Bräutigam M: Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002;205:271-277.
6. Lübbe J, Frielander SF, Cribier B, Morren MA, Garcia-Diez A, Gelmetti C, Hofmann H, Houwing RH, Kownacki S, Langley RGB, Virtanen M, Wolff K, McGeown C, Abrams B, Schneider D: Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice. Am J Clin Dermatol 2006;7:121-131.
7. Simon D, Lübbe J, Wüthrich B, Wiesner A, Weber MM, Laffitte E, Anliker MD, Schöni MH, Braathen LR, Schmid-Grendelmeier P, Gilgen Bobalj N, Scheider D: Benefits from the use of a pimecrolimus-based treatment in the management of atopic dermatitis in clinical practice. Dermatology 2006;213:313-318.
8. Krejci-Manwaring J, Tusa MG, Carroll C, Camacho F, Kaur M, Carr D, Fleischer AB, Balkrishnan R, Feldman SR: Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol 2007;56:211-216.
9. Zuberbier T, Heinzerling L, Bieber T, Schauer U, Klebs S, Bräutigam M: Steroid-sparing effect of pimecrolimus cream 1% in children with severe atopic dermatitis. Dermatology 2007;215:325-330.
10. Meurer M, Fartasch M, Albrecht G, Vogt T, Worm M, Ruzicka T, Altmeyer PJ, Schneider D, Weidinger G, Bräutigam M: Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 2004;208:365-372.
11. Niren N, Chang J, Wang Q, Sung J: Impact of atopic dermatitis treatment on parent's quality of life: results from findings in atopic children with eczema (FACE) study (poster abstract P719). J Am Acad Dermatol 2005;52:71.
12. McKenna S, Matheson R, Gulliver W, Abrams B: Impact of pimecrolimus cream 1% on quality of life in atopic dermatitis: results from the 6-month, naturalistic NOBEL study (poster abstract P720). J Am Acad Dermatol 2005;52:71.
13. Margolis DJ, Hoffstad O, Bilker W: Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 2007;214:289-295.